Holen Sie sich die Stockscreener-App
1.76
1.68%
-0.03
Schlusskurs vom Vortag:
$1.79
Offen:
$1.82
24-Stunden-Volumen:
132.22K
Relative Volume:
1.42
Marktkapitalisierung:
$13.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.92M
KGV:
-0.412
EPS:
-4.2716
Netto-Cashflow:
$-20.51M
1W Leistung:
+6.02%
1M Leistung:
+29.41%
6M Leistung:
+21.38%
1J Leistung:
+61.47%
1-Tages-Spanne:
$1.75
$1.85
1-Wochen-Bereich:
$1.59
$1.86
52-Wochen-Spanne:
$0.88
$9.56
Biovie Inc Stock (BIVI) Company Profile
Firmenname
Biovie Inc
Sektor
Branche
Telefon
775-888-3162
Adresse
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.76 | 13.27M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-15 | Eingeleitet | B. Riley Securities | Buy |
Biovie Inc Aktie (BIVI) Neueste Nachrichten
Biovie Files To Offer Up To $300 Million In SecuritiesSEC Filing - TradingView
BioVie (NASDAQ: BIVI) files $300M shelf registration to sell securities - Stock Titan
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioVie Inc (BIVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIVI Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating ExpensesAdjusted Earnings Analysis - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss Than Expected as Pipeline Progress ContinuesEnergy Earnings Report - newsline.com
BIVI Q1 2026 Earnings: EPS Beat Amid Clinical Progress; Stock DeclinesShare Repurchase Impact - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareh - GuruFocus
Law firm investigates BioVie officers for possible breach of duties to shareholders - Pluang
BioVie Inc. (BIVI) Q1 2026 Earnings: EPS Surpasses Estimates Despite Ongoing Revenue VoidEarnings Call Highlights - newsline.com
BIVI Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines on No Revenue StreamTrough Earnings Signal - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Barchart.com
Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases - Kavout
BIVI: Imminent clinical data for Parkinson's and long COVID could unlock major commercial opportunities - TradingView
BioVie Deadline Alert - TMX Newsfile
BioVie Inc. Warrant (BIVIW) Holds Steady Near Support – Waiting for a CatalystProfitability Factor - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss than Expected as Clinical Pipeline AdvancesTrough Earnings Signal - newsline.com
BioVie: Long COVID trial fully enrolled – ICYMI - Yahoo Finance
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
BioVie Inc. (BIVI) Hovers Near Key Support Levels as Stock Remains FlatAdvance Decline Line - The Legal Advocate
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 - Weekly Voice
BioVie to highlight neuro and liver disease programs in June 2 investor webinar - Proactive financial news
BioVie Inc. (BIVI) Declines 5.26%, Testing Key Support Near $1.37Dealer Gamma - The Legal Advocate
BioVie Inc. (BIVI) Declines 5.26%, Testing Critical Support Near $1.37BPI Bear Confirmed - The Legal Advocate
BIVI Q1 2026 Earnings: EPS Beats Estimates Despite No Revenue, Stock DropsEstimate Accuracy - The Legal Advocate
Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news
BioVie completes enrollment in Long COVID trial as need for treatments grows - Proactive financial news
BioVie Inc. (BIVI) Faces Selling Pressure as Shares Slide 5.9%Momentum Trade - The Legal Advocate
BioVie (BIVI) Completes Enrollment for Phase 2 Trial of Bezister - GuruFocus
BioVie completes enrollment in Phase 2 Long COVID trial - Yahoo! Finance Canada
BioVie completes enrollment in Long COVID treatment trial - Investing.com
BioVie completes enrollment in Long COVID treatment trial By Investing.com - Investing.com Nigeria
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - The Manila Times
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of - GlobeNewswire
BioVie Inc. (BIVI) Gains 2.7% as Shares Test Near-Term ResistanceQuality Factor - The Legal Advocate
BioVie Inc. (BIVI) Q1 2026 Earnings: Narrowing Losses and Clinical Progress Buoy Investor SentimentStrong Earnings Momentum - Newser
BioVie Inc.Common stock (NQ: BIVI - The Chronicle-Journal
BioVie (BIVI) Delivers Q1 2026 Beat — EPS $-0.70 vs $-0.74 ExpectedEarnings Deceleration Risk - newsline.com
BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3 - Bez Kabli
BioVie (BIVI) Rallies +1.53% as Bulls Target $1.40 2026-05-20Dividend Arbitrage - Newser
Finanzdaten der Biovie Inc-Aktie (BIVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):